---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-034898"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:50:50.052611+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aytu BioPharma Q1 net income $1.5M; promotes Ryan Selhorn as CFO

## Summary
- Net income of $1.5M vs net loss of $8.1M YoY; diluted EPS $0.15 loss vs $1.48 loss.
- Adjusted EBITDA $1.9M, down 21% from $2.4M; cash stable at $20.1M.
- ADHD Portfolio net revenue $15.3M (+1% YoY); Pediatric Portfolio up 54% sequentially.
- CFO Mark Oki terminated; Ryan Selhorn appointed CFO with base salary $400K.
- Board separated Chairman/CEO roles; John Donofrio appointed Chairman.

## SEC filing metadata
- accession: 0001437749-24-034898
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000143774924034898/0001437749-24-034898-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000143774924034898/aytu20240909_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-034898
- JSON: https://secwatch.observer/filing/0001437749-24-034898.json
- Plain text: https://secwatch.observer/filing/0001437749-24-034898.txt

## Key facts
- Executive change
  Ryan Selhorn was appointed as Chief Financial Officer, Corporate Secretary and Treasurer at AYTU BIOPHARMA, INC.
  - Action: appointed
  - Role: Chief Financial Officer, Corporate Secretary and Treasurer
  source text: On November 11, 2024, the board of directors of the Company (the " Board ") appointed Ryan Selhorn as Chief Financial Officer, Corporate Secretary and Treasurer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1385818/000143774924034898/0001437749-24-034898-index.htm
- Executive change
  Mark K. Oki was terminated as Chief Financial Officer at AYTU BIOPHARMA, INC.
  - Action: terminated
  - Role: Chief Financial Officer
  source text: On November 11, 2024, Mark K. Oki was terminated as Chief Financial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1385818/000143774924034898/0001437749-24-034898-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.